Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 218

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 218
---
 15, 2025. The exercise price is $100 per share, and the options expire on June
23, 2034.

The aggregate grant date fair value
of options granted in 2024 was approximately $808. The fair value of the Company’s share options granted was estimated using the
black Scholes model with the following assumptions:

| Description                 |     | 2024 grants |                |   |
| Risk-free interest rate     |     |             |   4.34% – 4.53 | % |
| Expected volatility         |     |             | 111.8% – 113.2 | % |
| Dividend yield              |     |             |              0 | % |
| Contractual life (in years) |     |             |             10 |   |

<div align='center'>F-26</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 8 – SHAREHOLDERS’ EQUITY (Cont.)

Successor:

| 1. | Amendment to the Company’s Global Share Incentive Plan (2021), increasing the number of shares available for issuance under Company’s Global Share Incentive Plan (2021) to 20,000,000 (the “Plan Amendment”). The Plan Amendment became effective on the date of the approval by the Board of Directors, but it is subject to approval by the holders of a majority of the voting power of the Company within 12 months, pursuant to section 422(b)(1) of the Internal Revenue Code. |

| 2. | A grant to the Successor’s former Chief Executive Officer 3,800,000 stock options at an exercise price of $0.001 per share. 1,900,000 options were fully vested upon grant and the remaining 1,900,000 options are scheduled to vest on a quarterly basis over two years in equal quarterly instalments of 237,500 options, beginning with the quarter ended March 31, 2024. The options are exercisable within eight years from grant date. The aggregate grant date fair value of such options was approximately $4,770. |

| 3. | A grant to the Chairman of the Board 160,000 stock options at an exercise price of $0.40 per share. 80,000 options were fully vested upon grant and the remaining 80,000 options